Compounds > angiotensin i, ile(5)-
Page last updated: 2024-11-10

angiotensin i, ile(5)-

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID3081372
CHEMBL ID262670
CHEBI ID2718
MeSH IDM0134069

Synonyms (41)

Synonym
unii-9c880yqg7c
angiotensin i, 5-l-isoleucine-
5-ile-angiotensin i
(ile5)-angiotensin i
l-leucine, n-(n-(n-(1-(n-(n-(n-(n-(n2-l-alpha-aspartyl-l-arginyl)-l-valyl)-l-tyrosyl)-l-isoleucyl)-l-histidyl)-l-prolyl)-l-phenylalanyl)-l-histidyl)-
angiotensin i, isoleucine(5)-
484-42-4
angiotensin i (human)
angiotensin i 5-isoleucine
9c880yqg7c ,
angiotensin i, ile(5)-
angiotensin i (rat)
leucine, n-(n-(n-(1-(n-(n-(n-(n-(n2-l-alpha-aspartyl-l-arginyl)-l-valyl)-l-tyrosyl)-l-isoleucyl)-l-histidyl)-l-prolyl)-3-phenylalanyl)-l-histidyl)-, l-
angiotensin i (callithrix jacchus gene angt)
angiotensin i (mouse)
5-l-isoleucine-angiotensin i
5-isoleucine-angiotensin i
(ile5)-ang i
pepsitensin
proangiotensin
C00873 ,
NCGC00167129-01
human angiotensin i
CHEMBL262670
chebi:2718 ,
AC1MIWSO ,
l-aspartyl-l-arginyl-l-valyl-l-tyrosyl-l-isoleucyl-l-histidyl-l-prolyl-l-phenylalanyl-l-histidyl-l-leucine
9041-90-1
angiotensin i (human, mouse, rat)
ORWYRWWVDCYOMK-HBZPZAIKSA-N
d-r-v-y-i-h-p-f-h-l
drvyihpfhl
l-asp-l-arg-l-val-l-tyr-l-ile-l-his-l-pro-l-phe-l-his-l-leu
l-alpha-aspartyl-l-arginyl-l-valyl-l-tyrosyl-l-isoleucyl-l-histidyl-l-prolyl-l-phenylalanyl-l-histidyl-l-leucine
CS-7599
AKOS024456668
mfcd00167405
HY-P1032
Q32039285
angiotensin 1 human
DTXSID80866222
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
neurotransmitter agentA substance used for its pharmacological action on any aspect of neurotransmitter systems. Neurotransmitter agents include agonists, antagonists, degradation inhibitors, uptake inhibitors, depleters, precursors, and modulators of receptor function.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
peptide zwitterionZwitterionic form of any peptide where, in general, the amino terminus is positively charged and the carboxy terminus is negatively charged.
angiotensin
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (39)

PathwayProteinsCompounds
ACE Inhibitor Pathway, Pharmacodynamics195
Benazepril Action Pathway34
Captopril Action Pathway33
Cilazapril Action Pathway34
Enalapril Action Pathway34
Fosinopril Action Pathway34
Lisinopril Action Pathway33
Moexipril Action Pathway34
Perindopril Action Pathway35
Quinapril Action Pathway34
Ramipril Action Pathway34
Rescinnamine Action Pathway33
Spirapril Action Pathway34
Trandolapril Action Pathway34
Candesartan Action Pathway74
Eprosartan Action Pathway74
Forasartan Action Pathway43
Irbesartan Action Pathway74
Losartan Action Pathway74
Olmesartan Action Pathway74
Telmisartan Action Pathway74
Valsartan Action Pathway74
Angiotensin Metabolism32
Temocapril Action Pathway34
Renin-angiotensin-aldosterone system (RAAS)011
Kidney Function - Ascending Limb of The Loop of Henle136
Kidney Function - Collecting Duct2011
Kidney Function - Distal Convoluted Tubule1810
SARS-CoV-2 and ACE2 receptor: molecular mechanisms04
Renin-angiotensin pathway (COVID-19 Disease Map)116
SARS-CoV-2 coagulation pathway (COVID-19 Disease Map)14
Conversion of angiotensinogen to angiotensin II42
Deregulation of renin-angiotensin system by SARS-CoV infection04
RAS and bradykinin pathways in COVID-19113
Mitochondrial immune response to SARS-CoV-285
Non-classical role of vitamin D86
SARS-CoV-2 mitochondrial chronic oxidative stress and endothelial dysfunction75
Renin-angiotensin system110
ACE inhibitor pathway09

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency112.20200.010039.53711,122.0200AID1479
DNA polymerase kappa isoform 1Homo sapiens (human)Potency21.19230.031622.3146100.0000AID588579
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
kidney developmentReninHomo sapiens (human)
mesonephros developmentReninHomo sapiens (human)
angiotensin maturationReninHomo sapiens (human)
renin-angiotensin regulation of aldosterone productionReninHomo sapiens (human)
proteolysisReninHomo sapiens (human)
regulation of blood pressureReninHomo sapiens (human)
male gonad developmentReninHomo sapiens (human)
hormone-mediated signaling pathwayReninHomo sapiens (human)
response to lipopolysaccharideReninHomo sapiens (human)
response to immobilization stressReninHomo sapiens (human)
drinking behaviorReninHomo sapiens (human)
regulation of MAPK cascadeReninHomo sapiens (human)
cell maturationReninHomo sapiens (human)
amyloid-beta metabolic processReninHomo sapiens (human)
response to cAMPReninHomo sapiens (human)
response to cGMPReninHomo sapiens (human)
cellular response to xenobiotic stimulusReninHomo sapiens (human)
juxtaglomerular apparatus developmentReninHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
aspartic-type endopeptidase activityReninHomo sapiens (human)
signaling receptor bindingReninHomo sapiens (human)
insulin-like growth factor receptor bindingReninHomo sapiens (human)
protein bindingReninHomo sapiens (human)
peptidase activityReninHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
extracellular regionReninHomo sapiens (human)
extracellular spaceReninHomo sapiens (human)
plasma membraneReninHomo sapiens (human)
apical part of cellReninHomo sapiens (human)
extracellular spaceReninHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID198996The compound was tested for its antihypertensive activity against human renin1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Inhibition of the renin-angiotensin system. A new approach to the therapy of hypertension.
AID1133749Pressor activity in rat assessed as weight basis relative to mammalian [Val5]angiotensin 21977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Synthesis and specific pressor activity of [1-aspartic acid,5-valine,9-serine]angiotensin I ("fowl angiotensin I").
AID1133747Pressor activity in rat assessed as weight basis relative to mammalian [Ile5]angiotensin 21977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Synthesis and specific pressor activity of [1-aspartic acid,5-valine,9-serine]angiotensin I ("fowl angiotensin I").
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
captopril
Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.		1.9610alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
angiotensin ii
Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).		2.8840amino acid zwitterion;
angiotensin II		human metabolite
angiotensin iii, 5-ile-
[no description available]		2.3720peptide
ramipril
Ramipril: A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.. ramipril : A dipeptide that is the prodrug for ramiprilat, the active metabolite obtained by hydrolysis of the ethyl ester group. An angiotensin-converting enzyme (ACE) inhibitor, used to treat high blood pressure and congestive heart failure.. quark : Quarks comprise one of two classes of the fundamental particles. Quarks possess fractional electric charges and are not observed in free state. The word "quark" first appears in James Joyce's Finnegans Wake and has been chosen by Murray Gell-Mann as a name for fundamental building blocks of particles.		1.9710azabicycloalkane;
cyclopentapyrrole;
dicarboxylic acid monoester;
dipeptide;
ethyl ester		bradykinin receptor B2 agonist;
cardioprotective agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
matrix metalloproteinase inhibitor;
prodrug
pepstatin
pepstatin: inhibits the aspartic protease endothiapepsin		1.9610pentapeptide;
secondary carboxamide		bacterial metabolite;
EC 3.4.23.* (aspartic endopeptidase) inhibitor
angiotensin i
Angiotensin I: A decapeptide that is cleaved from precursor angiotensinogen by RENIN. Angiotensin I has limited biological activity. It is converted to angiotensin II, a potent vasoconstrictor, after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME.. angiotensin I : A ten amino acid peptide formed by renin cleavage of angiotensinogen. Angiotensin I has no direct biological function except that high levels can stimulate catecholamine production. It is metabolized to its biologically active byproduct angiotensin II, a potent vasoconstrictor, by angiotensin converting enzyme (ACE) through cleavage of the two terminal amino acids.. angiotensin I dizwitterion : A peptide zwitterion that is the dizwitterionic form of angiotensin I having both carboxy groups deprotonated and the aspartyl amino group and arginine side-chain protonated. It is the major species at pH 7.3.		2.6630angiotensin;
peptide zwitterion		human metabolite;
neurotransmitter agent
angiotensin iii
Angiotensin III: A heptapeptide formed from ANGIOTENSIN II after the removal of an amino acid at the N-terminal by AMINOPEPTIDASE A. Angiotensin III has the same efficacy as ANGIOTENSIN II in promoting ALDOSTERONE secretion and modifying renal blood flow, but less vasopressor activity (about 40%).		2.3720
ConditionIndicatedRelationship StrengthStudiesTrials
Blood Pressure, High
[description not available]		02.3720
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		02.3720